When the best is the enemy of the good: the case of bone-marrow mononuclear cells to treat ischemic syndromes
- PMID: 23449595
- PMCID: PMC3659925
- DOI: 10.3324/haematol.2013.086231
When the best is the enemy of the good: the case of bone-marrow mononuclear cells to treat ischemic syndromes
References
-
- FDA Guidance for Industry: Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Small Entity Compliance Guide (2007). Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn... (accessed 13th of January, 2013).
-
- Regulation (EC) no 1394/2007 of the European parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union, 10.12.2007; L 324:121–37
-
- DeFrancesco L. Adult stem cell therapies walk the line. Nat Biotechnol. 2012;30(8):739–41 - PubMed
-
- European Medicines Agency Summaries of scientific recommendations on classification of advanced-therapy medicinal products. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/gen... (accessed 13th of January, 2013).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical